The target mono- and bis-(6-pyrazolyltriazolo-thiadiazine)
derivatives
4a-c
and
6a-d
were synthesized
using a straightforward
protocol via reaction of 3-bromoacetylpyrazole
2
with
4-amino-
s
-triazole-3-thiols
3a-c
and
bis(4-amino-5-mercapto-
s
-triazol-3-yl)alkanes
5a-d
, respectively. The bis(6-pyrazolyl-
s
-triazolo[3,4-
b
][1,3,4]thiadiazine) derivatives
8a
,
b
and
10
were also constructed
by reaction of the triazolo[3,4-
b
][1,3,4]thiadiazine-3-thiol
4c
with the proper dibromo compounds
7a
,
b
and
9
, respectively. Structures of the new
substances were determined by spectroscopic and analytical data. Compounds
4b
,
4c
, and
6a
showed potent cytotoxicity
against MCF-7 (IC
50
= 3.16, 2.74, and 0.39 μM, respectively)
and were safe against the MCF-10A cells. Compounds
4b
,
4c
, and
6a
also showed promising dual
EGFR and CDK-2 inhibition activities, particularly
6a
was the most effective (IC
50
= 19.6 and 87.9 nM, respectively),
better than Erlotinib and Roscovitine. Compound
6a
treatment
induced EGFR and CDK-2 enzyme inhibition by 97.18% and 94.11%, respectively,
at 10 μM (the highest concentration). Compound
6a
notably induced cell apoptosis in MCF-7 cells, increasing the cell
population by total apoptosis 43.3% compared to 1.29% for the untreated
control group, increasing the cell population at the S-phase by 39.2%
compared to 18.6% (control).